Genetics of Alzheimer's disease
The DOI matches its Crossref record.
Abstract
Mutations in any one of three genes can cause autosomal dominant, early-onset Alzheimer's disease: these genes are the amyloid precursor protein (APP) gene on chromosome 21, the presenilin-1 (PS-1) gene on chromosome 14 and the presenilin-2 (PS-2) gene on chromosome 1. Pathogenic mutations at all these loci cause mismetabolism of APP such that more of the peptide A beta 42 is produced. This peptide is deposited in the plaques in the brains of Alzheimer's patients. These facts have led to the dominant hypothesis for the disease process: the 'amyloid cascade hypothesis', which proposes that overproduction or failure to clear the peptide A beta 42 is always central to the disease. Genetic variability at the apoliprotein E locus is a major determinant of late onset Alzheimer's disease. The mechanism by which apoliprotein E is involved in the pathogenesis of Alzheimer's disease is not yet known. There are likely to be other genetic factors which impinge on Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in the genes for amyloid precursor protein (APP) and presenilins (PS1, PS2) increase production of 𝛃 -amyloid 42 (A 𝛃 42 ) and cause familial Alzheimer's disease (FAD).”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Hutton et al., 1998
In the citing paper
“A strong genetic association exists between earlyonset familial forms of AD (FAD) and the 42 amino acid species of the A 𝛃 peptide (A 𝛃 42 ) (for review, see Hutton et al., 1998; Younkin, 1998; Sisodia et al., 1999).”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Hutton et al., 1998
Citations
Cites
Still being checked.
Cited by
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Molecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740
Behavioral phenotype of individuals with Down syndrome
Chapman, R. S., & Hesketh, L. J. (2000) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/1098-2779(2000)6:2<84::aid-mrdd2>3.0.co;2-p · Cited by 672
The Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Phosphatidylethanolamine Metabolism in Health and Disease
(2016) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2015.10.001 · Cited by 526
BACE1: The β-Secretase Enzyme in Alzheimer's Disease
Vassar, R. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:105 · Cited by 370
β-Secretase (BACE) as a drug target for alzheimer’s disease
Vassar, R. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00157-6 · Cited by 210
The β-Secretase, BACE: A Prime Drug Target for Alzheimer's Disease
Vassar, R. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:157 · Cited by 186
Sun, Y.-X., Minthon, L., Wallmark, A., Warkentin, S., Blennow, K., & Janciauskiene, S. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000071001 · Cited by 180
Statin therapy for Alzheimer’s disease
Petanceska, S. S., DeRosa, S., Olm, V., Diaz, N. S., Sharma, A., Bryant‐Thomas, T., Duff, K., Pappolla, M. A., & Refolo, L. M. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0026-2 · Cited by 152
Insights into Manganese Superoxide Dismutase and Human Diseases
Liu, M., Sun, X., Chen, B., Dai, R., Xi, Z., & Xu, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415893 · Cited by 167
Genetic Association of a Cystatin C Gene Polymorphism With Late-Onset Alzheimer Disease
Finckh, U. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1579 · Cited by 141
Branched KLVFF Tetramers Strongly Potentiate Inhibition of β‐Amyloid Aggregation
Chafekar, S. M., Malda, H., Merkx, M., Meijer, E. W., Viertl, D., Lashuel, H. A., Baas, F., & Scheper, W. (2007) · ChemBioChem · doi:10.1002/cbic.200700338 · Cited by 141
FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction
Flood, D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00330-x · Cited by 131
Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease
Hölscher, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00088 · Cited by 117
Oligomer-specific Aβ toxicity in cell models is mediated by selective uptake
Chafekar, S. M., Baas, F., & Scheper, W. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.06.003 · Cited by 133
Diesel engine exhaust accelerates plaque formation in a mouse model of Alzheimer’s disease
Hullmann, M., Albrecht, C., van Berlo, D., Gerlofs-Nijland, M. E., Wahle, T., Boots, A. W., Krutmann, J., Cassee, F. R., Bayer, T. A., & Schins, R. P. F. (2017) · Particle and Fibre Toxicology · doi:10.1186/s12989-017-0213-5 · Cited by 111
Synaptic transmission block by presynaptic injection of oligomeric amyloid beta
Moreno, H., Yu, E., Pigino, G., Hernandez, A. I., Kim, N., Moreira, J. E., Sugimori, M., & Llinás, R. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900944106 · Cited by 107
Brooks, D. J. (2005) · Neurotherapeutics · doi:10.1602/neurorx.2.2.226 · Cited by 107
Walker, L. C., & LeVine, H. (2000) · Molecular Neurobiology · doi:10.1385/mn:21:1-2:083 · Cited by 117
Urano, T., & Tohda, C. (2010) · Phytotherapy Research · doi:10.1002/ptr.3183 · Cited by 101
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Vassar, R., & Cole, S. (2007) · Current Genomics · doi:10.2174/138920207783769512 · Cited by 84
Kaczorowski, C. C., Sametsky, E., Shah, S., Vassar, R., & Disterhoft, J. F. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.09.003 · Cited by 98
Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease
Wu, Z., Ciallella, J. R., Flood, D. G., O’Kane, T. M., Bozyczko‐Coyne, D., & Savage, M. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.010 · Cited by 96
Hölscher, C. (2005) · Reviews in the Neurosciences · doi:10.1515/revneuro.2005.16.3.181 · Cited by 82
Lipid peroxidation in brain during aging in the senescence-accelerated mouse (SAM)
Pétursdóttir, A., Farr, S. A., Morley, J. E., Banks, W. A., & Skúladóttir, G. V. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.033 · Cited by 82
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
(2010) · Europe PMC (PubMed Central)
Cholinergic deafferentation of the rabbit cortex: a new animal model of Aβ deposition
Beach, T. G., Potter, P. E., Kuo, Y.-M., Emmerling, M. R., Durham, R. A., Webster, S. D., Walker, D. G., Sue, L. I., Scott, S., Layne, K. J., et al. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00916-2 · Cited by 71
Rosario, D., Boren, J., Uhlen, M., Proctor, G., Aarsland, D., Mardinoglu, A., & Shoaie, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00716 · Cited by 67
Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease
Ji, C., Xue, G.-F., Li, G., Li, D., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0021 · Cited by 68
Alzheimer’s disease: epidemiology, genetics, and beyond
Wang, X., & Ding, H. (2008) · Neuroscience Bulletin · doi:10.1007/s12264-008-0105-7 · Cited by 81
Inhibition of BACE, a Promising Approach to Alzheimers Disease Therapy
Roggo, S. P. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026024607490 · Cited by 66
Takashima, A. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1090 · Cited by 57
Cell death pathology: Perspective for human diseases
Agostini, M., Tucci, P., & Melino, G. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.09.081 · Cited by 66
Zeng, J., Libien, J. M., Shaik, F., Wolk, J., & Hernandez, A. I. (2016) · Neural Plasticity · doi:10.1155/2016/8987928 · Cited by 60
Candore, G., Balistreri, C. R., Grimaldi, M. P., Vasto, S., Listì, F., Chiappelli, M., Licastro, F., Lio, D., & Caruso, C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1386.008 · Cited by 60
β-Secretase, APP and Aβ in Alzheimer’s Disease
Vassar, R. J. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_4 · Cited by 53
Dysregulation of calcium in Alzheimer's disease
Brzyska, M., & Elbaum, D. (2003) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2003-1465 · Cited by 50
Developmental mechanisms in the pathogenesis of neurodegenerative diseases
Mehler, M. F., & Gökhan, Ş. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00052-6 · Cited by 42
Beach, T. G., Kuo, Y., Schwab, C., Walker, D. G., & Roher, A. E. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02076-6 · Cited by 42
Intracellular cholesterol homeostasis and amyloid precursor protein processing
Burns, M. P., & Rebeck, G. W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.004 · Cited by 42
Monitoring β‐Secretase Activity in Living Cells with a Membrane‐Anchored FRET Probe
Folk, D. S., Torosian, J. C., Hwang, S., McCafferty, D. G., & Franz, K. J. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206673 · Cited by 38
Jagota, S., & Rajadas, J. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0386-2 · Cited by 37
Frederikse, P. H., & Ren, X. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64475-6 · Cited by 36
Autiero, I., Langella, E., & Saviano, M. (2013) · Molecular BioSystems · doi:10.1039/c3mb70235a · Cited by 33
Family history of dementia is a risk factor for Lewy body disease
Woodruff, B. K., Graff‐Radford, N. R., Ferman, T. J., Dickson, D. W., DeLucia, M. W., Crook, J. E., Arvanitakis, Z., Brassler, S., Waters, C., Barker, W., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000219812.20616.b3 · Cited by 31
Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning
Castillo-Barnés, D., Su, L., Ramírez, J., Salas-Gonzalez, D., Martínez-Murcia, F. J., Illán, I. A., Segovia, F., Ortíz, A., Cruchaga, C., Farlow, M. R., et al. (2020) · Information Fusion · doi:10.1016/j.inffus.2020.01.001 · Cited by 32
Genetics of neurological disorders
Faghihi, M. A., Mottagui‐Tabar, S., & Wahlestedt, C. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.317 · Cited by 26
Ramírez, M. J., Heslop, K. E., Francis, P. T., & Rattray, M. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02580-x · Cited by 31
Ahmad, A., Muzaffar, M., & Ingram, V. M. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.06.022 · Cited by 26
Use of in Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease
Burns, M. P., & Duff, K. (2003) · Neurochemical Research · doi:10.1023/a:1023294820218 · Cited by 23
Navarro‐Hortal, M. D., Romero‐Márquez, J. M., Osta, S., Jiménez-Trigo, V., Muñoz-Ollero, P., & Varela‐López, A. (2022) · Diseases · doi:10.3390/diseases10020028 · Cited by 19
Kim, J.-S., Bareiss, S. K., Kim, K. K., Tatum, R., Han, J.-R., Jin, Y. H., Kim, H., Lu, Q., & Kim, K. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.135 · Cited by 18
Interaction of Proteins Involved in Neuronal Proteinopathies
Kulichikhin, K. Y., Malikova, O. A., Zobnina, A. E., Zalutskaya, N. M., & Rubel, A. A. (2023) · Life · doi:10.3390/life13101954 · Cited by 19
In silico investigation and targeting of amyloid β oligomers of different size
Autiero, I., Saviano, M., & Langella, E. (2013) · Molecular BioSystems · doi:10.1039/c3mb70086k · Cited by 20
Paudel, B., Jeong, S., Peña-Martinez, C., Rickman, A. D., Haluck-Kangas, A., Bartom, E. T., Fredriksen, K., Affaneh, A., Kessler, J. A., Mazzulli, J. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44465-8 · Cited by 18
Population-based gene discovery in the post-genomic era
Zak, N. B., Shifman, S., Shalom, A., & Darvasi, A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02007-4 · Cited by 15
Mishra, S., Swain, P. S., Pati, S., & Dehury, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41414 · Cited by 17
Development of vaccination approaches for the treatment of neurological diseases
Federoff, H. (2009) · The Journal of comparative neurology · doi:10.1002/cne.22034 · Cited by 13
Monitoring β‐Secretase Activity in Living Cells with a Membrane‐Anchored FRET Probe
Folk, D. S., Torosian, J. C., Hwang, S., McCafferty, D. G., & Franz, K. J. (2012) · Angewandte Chemie · doi:10.1002/ange.201206673 · Cited by 6
Alzheimer’s disease: a step closer to understanding type 3 diabetes in African Americans
Ferguson, S. A., Panos, J., Sloper, D. T., Varma, V., & Sarkar, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00754-z · Cited by 6
Paudel, B., Jeong, S., Peña-Martinez, C., Rickman, A. D., Haluck-Kangas, A., Bartom, E. T., Fredriksen, K., Affaneh, A., Kessler, J. A., Mazzulli, J. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.08.507157 · Cited by 5
Etiology and Histopathology of Alzheimer’s Disease and Current Approaches
Erdemci, F., Aşir, F., & Taş, F. (2022) · Black Sea Journal of Health Science · doi:10.19127/bshealthscience.1064168 · Cited by 4
Kalecký, K., Buitrago, L., Alarcón, J. M., Singh, A., Bottiglieri, T., Kaddurah‐Daouk, R., & Hernández, A. I. (2026) · Scientific Reports · doi:10.1038/s41598-026-42518-8 · Cited by 5
Pathological Roles of INPP5D in Alzheimer’s Disease
Chu, Y. N., Akahori, A., Takatori, S., & Tomita, T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-31978-5_30 · Cited by 4
Josset, S., Orsolini, P., Siqueira, G. D. F., Alvaro, T., Tingaut, P., & Zimmermann, T. (2014) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.32932 · Cited by 4
Murray, M. J., & Murray, C. F. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2215-2.50123-x · Cited by 2
La malattia di Alzheimer e la sindrome di Down: un infelice connubio
Cipriani, G., Picchi, L., Dolciotti, C., & Bonuccelli, U. (2011) · Quaderni Italiani di Psichiatria · doi:10.1016/j.quip.2010.12.001 · Cited by 2
Current and future treatments for Alzheimer's disease
Morinan, A. (2001) · Nursing and Residential Care · doi:10.12968/nrec.2001.3.3.7921 · Cited by 2
Pedersen, W. A. (2007) · Elsevier eBooks · doi:10.1016/b978-008055232-3.60662-2 · Cited by 2
Bum, K. E., 조준용, & 김창환 (2014) · Exercise Science · doi:10.15857/ksep.2014.23.2.99 · Cited by 1
Activity profile-based siRNA screen to explore the functional genomics of Alzheimer's disease
Marine, S., Stec, E. M., Chase, P. S., Hoffman, I., Szymanski, S., Simon, A. J., Shi, X., Bartz, S. R., Bagchi, A., Minch, E., et al. (2007) · BioTechniques · doi:10.2144/000112700 · Cited by 1
Part V. Genetic advances and biological markers for alzheimer's disease
Galasko, D. (2000) · Disease-a-Month · doi:10.1016/s0011-5029(00)90006-3 · Cited by 1
Shafi, V., & Siddiqui, I. (2024) · Research Square · doi:10.21203/rs.3.rs-4408464/v1 · Cited by 1
Kalecký, K., Buitrago, L., Alarcón, J. M., Singh, A., Bottiglieri, T., Kaddurah-Daouk, R. F., & Hernandez, A. I. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.17.633452 · Cited by 1
Chen, C. (2014) · UKnowledge (University of Kentucky)
Marine Natural Products for Protein Misfolding Modulation
James, C., & Vanya, K. (2013) · InTech eBooks · doi:10.5772/54585
Population-based gene discovery in psychiatric diseases
Zak, N. B., Pisanté, A., & Darvasi, A. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.1.51
Pathogenesis of Alzheimer's Disease with Special Reference to Amyloid β Protein
Tamaoka, A. (2012) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.8.285 · Cited by 1
Cognitive Deficits in Neurodegenerative Disorders: Parkinson’s Disease and Alzheimer’s Disease
Bodis-Wollner, I. G., & Moreno, H. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_9
Bakir, I. (2010) · DiVA (Digitala Vetenskapliga Arkivet)
Anderson, H. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.05297-1
Metadata
- Authors
- Hutton, M., Pérez-Tur, J., & Hardy, J.
- Affiliations
- Mayo Clinic in Florida (US)
- Neurogenetics Laboratory, The Mayo Clinic Jacksonville, 4500 San Pablo Rd., Jacksonville, FL 32224, U.S.A.
- ORCID
- Hardy, John
- Venue
- Essays in Biochemistry
- Publisher
- Portland Press Ltd.
- Published
- 1998-12-01
- Volume
- 33
- Pages
- 117-131
- ISSN
- 0071-1365 (ISSN-L)
- 1744-1358
- OpenAlex
- W2205982756
- Cited by
- 88
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 4
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Essays in Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, genetic mutations, amyloid precursor protein gene, presenilin 1, presenilin 2, amyloid-beta 42, amyloid plaques, amyloid hypothesis, apolipoprotein E, late-onset Alzheimer's disease, autosomal dominant inheritance
- MeSH terms
- Aged, Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Genes, Dominant, Humans, Membrane Proteins, Middle Aged, Models, Molecular, Molecular Sequence Data, Mutation, Peptide Fragments, Risk Factors, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Age of Onset, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.